Diabetes Mellitus, Type 2, Obesity
Conditions
Keywords
Visceral fat
Brief summary
Focusing on newly diagnosed type 2 diabetes participants with overweight and obesity (24kg/m2 ≤ body mass index ≤ 30kg/m2). 50 participants per arm (acarbose & lifestyle combination / vildagliptin & lifestyle combination), using abdominal computed tomography scans and other methods to evaluate the effects of acarbose and vildagliptin on visceral fat distribution in overweight and obesity patients with newly diagnosed type 2 diabetes.
Interventions
DRUGAcarbose
1-2 week: 50mg tid; 3-24 week: 100mg tid.
DRUGVildagliptin
1-24 week: 50mg bid
Sponsors
Peking University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* All patients was diagnosed within the past 12 months with type 2 diabetes patients (WHO, 1999 criteria ). * Not received oral anti-diabetic drugs or has been on short-term(1month) treatment that had been discontinued 3 months before enrollment. * 30 ≤ Age ≤ 70 years old, male or female. * HbA1c between 7% and 9% (7.0% ≤ HbA1c ≤9.0%). * 24 ≤ BMI ≤ 30 kg/m2. * Written Informed consent.
Exclusion criteria
* Subject with type 1 diabetes or gestational diabetes mellitus and other specific types DM. * Those who can not tolerate AGI or who is suffering GI disease. * Subject with repeated severe hypoglycemia and/or unawareness of hypoglycemia. * Known or suspected allergy to trial product(s) or related products. * Females of child bearing potential who are pregnant, breast-feeding or have the intention of becoming pregnant or not using adequate contraceptive methods throughout the trial * Impaired liver function, defined as ALT≥2 or AST≥ 2 times upper referenced limit times upper normal limit. * Any other clinically significant condition or major systemic diseases, including serious coronary heart disease, cardiovascular disease, cancer, TB, acute infection. * Endocrine diseases (hypo thyroidism, hyperthyroidism,Cushing's syndrome). * Uncontrolled hypertension(SBP≥180mmHg and/or DBP≥100mmHg). * Diabetic ketoacidosis; or hyperosmolar non-ketotic coma. * Concomitant treatment which influences blood glucose and bodyweight. * Impaired renal function(Cr≥ 1.5 mg/dl in male or Cr≥1.4 mg/dl in female). * Mental disorders; drug or other substance misuse. * Participation in any drug clinical trials during the past 3 months before enrolment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of the visceral fat area in square centimeter assessed by abdominal CT scans from baseline to 24 weeks. | 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change of waist circumstance in centimeters measured by investigators from baseline to 24 weeks. | 24 weeks |
| Change of body mass index in kg/m^2 measured by investigators from baseline to 24 weeks. | 24 weeks |
| Change of the subcutaneous fat area in square centimeters assessed by abdominal CT scans from baseline to 24 weeks. | 24 weeks |
| Change of hemoglobin A1c in percents from baseline to 24 weeks. | 24 weeks |
| Change of hemoglobin fasting plasma glucose in millimols per liter from baseline to 24 weeks. | 24 weeks |
| Change of hemoglobin 2-hour-post-prandial plasma glucose in millimols per liter from baseline to 24 weeks. | 24 weeks |
| Change of body weight in kilograms measured by investigators from baseline to 24 weeks. | 24 weeks |
| Change of total cholesterol in millimols per liter from baseline to 24 weeks. | 24 weeks |
| Change of low-density lipoprotein-cholesterol in millimols per liter from baseline to 24 weeks. | 24 weeks |
| Change of high-density lipoprotein-cholesterol in millimols per liter from baseline to 24 weeks. | 24 weeks |
| Change of insulin in international units per liter from baseline to 24 weeks. | 24 weeks |
| Change of brain natriuretic peptide in nanograms per milliliter from baseline to 24 weeks. | 24 weeks |
| Change of triglyceride in millimols per liter from baseline to 24 weeks. | 24 weeks |
Countries
China
Contacts
Primary ContactLinong Ji, MD
Outcome results
None listed